hero section gradient
16 handpicked stocks

Live Entertainment Lawsuit: What's Next for Rivals

The FTC's lawsuit against Live Nation and Ticketmaster alleges monopolistic control and deceptive practices in the live event industry. This legal challenge could create significant opportunities for competing ticketing platforms and event promoters to gain market share.

Author avatar

Han Tan | Market Analyst

Published on September 19

Your Basket's Financial Footprint

Structured data capture of market capitalisation and investor key points for the specified stock basket.

Key Takeaways for Investors:
  • Large-cap dominance generally implies lower volatility and closer tracking to broad market movements.
  • Consider as a core portfolio holding rather than a speculative trade.
  • Likely to deliver steady, long-term value rather than rapid, short-term gains.
Total Market Cap
  • EB: $224.85M

  • TME: $38.64B

  • MSGE: $2.14B

  • Other

About This Group of Stocks

1

Our Expert Thinking

The FTC's lawsuit against Live Nation could disrupt the live entertainment industry's established order. With one company controlling roughly 80% of major concert venue ticketing, regulatory pressure may force operational changes and create openings for competitors to gain market share in this lucrative sector.

2

What You Need to Know

This group includes alternative ticketing platforms, event promoters, venue operators, and travel-tech companies with ticketing expertise. These stocks represent a tactical, event-driven opportunity focused on potential shifts in the competitive landscape of the global entertainment industry.

3

Why These Stocks

These companies were handpicked by professional analysts as potential beneficiaries of increased scrutiny on the market leader. They offer more transparent pricing, alternative event management solutions, or serve markets that could attract artists, venues, and consumers seeking alternatives.

Why You'll Want to Watch These Stocks

⚖️

Legal Disruption in Motion

The FTC lawsuit could force the industry's dominant player to change how it operates, potentially opening doors for competitors to capture significant market share.

🎫

Alternative Platforms Rising

Artists, venues, and consumers are increasingly seeking transparent pricing and better service, creating opportunities for innovative ticketing solutions to gain traction.

🚀

Market Share Up for Grabs

With 80% of major venue ticketing controlled by one company, even small shifts in market dynamics could translate to substantial growth for well-positioned alternatives.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Railroad Investment: Beyond the $85 Billion Merger

Railroad Investment: Beyond the $85 Billion Merger

Union Pacific and Norfolk Southern are seeking to merge, creating America's first transcontinental railroad. This landmark consolidation could drive significant investment into rail infrastructure and technology, creating opportunities for companies that support and equip the freight rail industry.

Oracle TikTok Deal May Boost Stocks in 2025

Oracle TikTok Deal May Boost Stocks in 2025

TikTok has finalized the sale of its U.S. operations to an investor group including Oracle, resolving national security concerns and securing its future in the American market. This development creates opportunities for companies in the digital advertising, social commerce, and creator economy sectors that can now capitalize on the platform's stabilized presence and massive user base.

Pharma Reshoring Explained | Manufacturing Investment

Pharma Reshoring Explained | Manufacturing Investment

Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.

Frequently Asked Questions